Medical Digest & Congress Report

Otto Metzger, MD presented late-breaking results of the phase 3 PATINA trial showing addition of CDK4/6 inhibitor palbociclib to standard therapy led to a 15-month improvement in PFS in HR+, HER2+ metastatic breast cancer at San Antonio Breast Cancer Symposium 2024.

Video: https://medicaldigest.org/scientific-contents/interview:palbociclib-shows-benefit-hr-her2-metastatic-breast-cancer-patina-trial

Matteo Lambertini, MD, PhD discusses an educational session focus on the management of breast cancer in young women at San Antonio Breast Cancer Symposium 2024.

Video: https://medicaldigest.org/scientific-contents/interview:breast-cancer-young-women

Katherine L. Nathanson, MD discusses reversion mutations in BRCA1/2 in response to therapy at San Antonio Breast Cancer Symposium 2024.

Video: https://medicaldigest.org/scientific-contents/interview:future-cancer-genetics-here-reversion-mutations-brca12-response-therapy

Kate Lathrop, MD discusses results from the phase III EMBER-3 clinical trial presented at San Antonio Breast Cancer Symposium 2024.

Video: https://medicaldigest.org/scientific-contents/interview:next-generation-serd-protects-against-progression-some-patients-advanced-breast-cancer-resistant-standard-hormone-therapy

Monica Morrow, MD, FACS discusses omission of axillary staging in ER positive breast cancer at San Antonio Breast Cancer Symposium 2024.

Video: https://medicaldigest.org/scientific-contents/interview:clinical-controversies-omission-axillary-staging-er-positive-breast-cancer-implications-adjuvant-therapies

Ismail Jatoi, MD, PhD, FACS discusses updates on breast cancer screening at San Antonio Breast Cancer Symposium 2024.

Video: https://medicaldigest.org/scientific-contents/interview:risk-reduction-and-early-detection-updates-breast-cancer-screening

Prof. Giuseppe Curigliano presents the data of the DESTINY-Breast06 at San Antonio Breast Cancer Symposium 2024.

Video: https://medicaldigest.org/scientific-contents/interview:efficacy-and-safety-trastuzumab-deruxtecan-vs-physicians-choice-chemotherapy-pace-disease-progression-prior-endocrine-based-therapy

Sara A Hurvitz, MD, FACP on the role of endocrine-based therapy in the management of breast cancer at San Antonio Breast Cancer Symposium 2024.

Video: https://medicaldigest.org/scientific-contents/interview:compelling-teaching-cases-focused-role-endocrine-based-therapy-management-breast-cancer

Prof. Robert Hills presents a comprehensive patient-level meta-analysis of three randomized trials demonstrated that compared with surgery deferral, immediate breast surgery significantly reduces both local progression and long-term mortality in women aged 70 years or older with operable breast cancer at San Antonio Breast Cancer Symposium 2024.

Video: https://medicaldigest.org/scientific-contents/interview:immediate-surgery-lowers-local-recurrence-older-breast-cancer-population

Judy E. Garber, MD, MPH presents updated results of the OlympiA study at San Antonio Breast Cancer Symposium 2024. The new analysis provides further support for olaparib’s benefits in patients with high-risk, HER2-negative breast cancer with germline mutations in BRCA1 or BRCA2.

Video: https://medicaldigest.org/scientific-contents/interview:parp-inhibition-shows-long-term-survival-benefits-patients-high-risk-brca-positive-breast-cancer-olympia-trial